Methallenestril API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Methallenestril API 517-18-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Methallenestril. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Methallenestril
- Synonyms:
- Metalenestrilo , Methallenestrilum
- Cas Number:
- 517-18-0
- DrugBank number:
- DB13143
- Unique Ingredient Identifier:
- XL025389JS
General Description:
Methallenestril is a chemical compound identified by the CAS number 517-18-0. It is known for its distinct pharmacological properties and applications.
Classification:
Methallenestril belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings, classified under the direct parent group Naphthalenes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Naphthalenes class, specifically within the None subclass.
Categories:
Methallenestril is categorized under the following therapeutic classes: Estrogens, Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital System, Synthetic Estrogens, Plain. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Methallenestril is a type of Genitourinary Agents
Genitourinary agents are a category of pharmaceutical active ingredients (APIs) that are specifically designed to target and treat disorders related to the genitourinary system. The genitourinary system encompasses the organs and structures involved in the production, storage, and elimination of urine, as well as the reproductive organs.
These APIs play a crucial role in the treatment of various genitourinary conditions, including urinary tract infections (UTIs), erectile dysfunction, urinary incontinence, benign prostatic hyperplasia (BPH), and other related disorders. They exert their therapeutic effects by interacting with specific receptors or enzymes in the genitourinary system, regulating physiological processes, and restoring normal function.
Some commonly used genitourinary agents include alpha-blockers, which relax the smooth muscles in the prostate and bladder neck, improving urine flow in patients with BPH. Additionally, phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are widely prescribed for erectile dysfunction, as they enhance blood flow to the penile tissues, facilitating erection.
These APIs are typically formulated into various dosage forms, such as tablets, capsules, creams, gels, or injections, allowing for convenient administration to patients. The development and production of genitourinary agents involve stringent quality control measures and compliance with regulatory guidelines to ensure safety, efficacy, and consistent product performance.
In summary, genitourinary agents form a crucial category of pharmaceutical APIs used to treat a range of disorders affecting the genitourinary system. Their targeted mechanisms of action and diverse dosage forms make them valuable tools in improving genitourinary health and enhancing patients' quality of life.
